These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Chimienti M, Cullen MT, Casadei G. Eur Heart J; 1995 Dec; 16(12):1943-51. PubMed ID: 8682031 [Abstract] [Full Text] [Related]
4. Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia. Hellestrand KJ. Am J Cardiol; 1996 Jan 25; 77(3):83A-88A. PubMed ID: 8607396 [Abstract] [Full Text] [Related]
5. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Henthorn RW, Waldo AL, Anderson JL, Gilbert EM, Alpert BL, Bhandari AK, Hawkinson RW, Pritchett EL. Circulation; 1991 Jan 25; 83(1):119-25. PubMed ID: 1898640 [Abstract] [Full Text] [Related]
13. Flecainide single oral dose for management of paroxysmal supraventricular tachycardia in children and young adults. Musto B, Cavallaro C, Musto A, D'Onofrio A, Belli A, De Vincentis L. Am Heart J; 1992 Jul 25; 124(1):110-5. PubMed ID: 1615792 [Abstract] [Full Text] [Related]
17. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. DiMarco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia E, McGovern B, Scheinman MM, Govier WC. Ann Intern Med; 1990 Jul 15; 113(2):104-10. PubMed ID: 2193560 [Abstract] [Full Text] [Related]